CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
REVENUES:
License fees	$ 175,419	$ 41,361	$ 211,887	$ 146,546
Royalties from product sales	126,455	177,244	273,857	393,230
Grant income	672,537	442,244	1,074,771	857,855
Sale of research products	59,253	119,520	127,037	208,607
Total revenues	1,033,664	780,369	1,687,552	1,606,238
Cost of sales	(83,918)	(24,816)	(105,497)	(24,831)
Total revenues, net	949,746	755,553	1,582,055	1,581,407
EXPENSES:
Research and development	(4,615,436)	(3,333,689)	(8,773,302)	(6,284,816)
General and administrative	(2,413,641)	(2,402,858)	(4,802,337)	(4,303,050)
Total expenses	(7,029,077)	(5,736,547)	(13,575,639)	(10,587,866)
Loss from operations	(6,079,331)	(4,980,994)	(11,993,584)	(9,006,459)
OTHER INCOME/(EXPENSES):
Interest income, net	3,355	5,124	11,636	11,851
Other income/(expense), net	85,260	(24,446)	(240,005)	50,007
Loss on sale of fixed assets	(3,546)	0	(3,546)	0
Total other income/(expense), net	85,069	(19,322)	(231,915)	61,858
NET LOSS	(5,994,262)	(5,000,316)	(12,225,499)	(8,944,601)
Less: Net loss attributable to the noncontrolling interest	537,040	722,388	1,796,378	1,302,379
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(5,457,222)	(4,277,928)	(10,429,121)	(7,642,222)
Foreign currency translation loss	(182,947)	(928,536)	(58,859)	(1,598,542)
COMPREHENSIVE NET LOSS	$ (5,640,169)	$ (5,206,464)	$ (10,487,980)	$ (9,240,764)
BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)	$ (0.11)	$ (0.09)	$ (0.21)	$ (0.16)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)	50,548,582	48,835,672	50,435,272	48,572,550